Atrovent HFA (ipratropium bromide hydrofluoroalkane inhalation) / Boehringer Ingelheim - LARVOL DELTA

Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients (PRNewswire) - "Boehringer Ingelheim's new program to cap out-of-pocket costs at $35 per month for eligible patientsi for the company's inhalers is now available. The program applies to all Boehringer Ingelheim inhalers, including: Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol. Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray. Spiriva HandiHaler (tiotropium bromide inhalation powder). Spiriva Respimat 1.25 mcg (tiotropium bromide) Inhalation Spray. Spiriva Respimat 2.5 mcg (tiotropium bromide) Inhalation Spray. Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray. Striverdi Respimat (olodaterol) Inhalation Spray."

Pricing • Asthma • Chronic Obstructive Pulmonary Disease

Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes (clinicaltrials.gov) - P4 | N=200 | Not yet recruiting | Sponsor: Ohio State University | Trial completion date: Mar 2028 ➔ Nov 2028 | Trial primary completion date: Mar 2027 ➔ Nov 2027

Trial completion date • Trial primary completion date • Asthma • Genetic Disorders • Immunology • Obesity • Pulmonary Disease • Respiratory Diseases